TAT-10: Reduction of Radiation Exposure to the Large Intestine During Ra223 Alpha Therapy with Oral Administration of Barium Sulfate

Kanazawa, Japan (UroToday.com) Ra223 alpha therapy has been shown to be effective in treating bone metastases of metastatic castration-resistant prostate cancer patients. However, some patients have shown gastrointestinal side effects such as nausea and diarrhea. In this mouse study, we investigate whether these side effects may be reduced by oral administration of barium sulfate (BaSO4), a co-precipitating agent of Ra. 

TAT-10: Pharmacokinetic Profiling and Therapeutic Efficacy of Alpha-emitter Labeled Ant-PD1.1 Antibodies in an Immune Competent Transgenic Breast Cancer Model

Kanazawa, Japan (UroToday.com) Normally tumors are vulnerable from T cells in the body’s  immune system. Some tumors have the ability to express Programed cell Death Ligand 1 (PD-L1) which inactivates the T cells allowing the tumor to survive. Previous studies have shown that treatment with anti-PD-1 antibodies have been effective in reducing many cancers including breast cancer. The aim of this study is to investigate if the anti-PD-1 immunotherapy can be enhanced when combined Ac225 targeted alpha therapy.

TAT-10: Novel IgG t Melanin Show Promise for Radioimmunotherapy of Metastatic Melanoma

Kanazawa, Japan (UroToday.com) Previous studies of treating metastatic melanoma using a murine antibody to melanin labeled with the beta-emitting isotope Re188  established safety and efficacy. However, that antibody (genotype IgM) presented obstacles to humanization. We recently identified an 8C3 murine antibody (genotype IgG) that is amenable to humanization. The purpose of the present study is evaluate 8C3 radio-labeled with Re188 and also the alpha-emitting isotope Bi213.

TAT-10: Preclinical Evaluation of Anti-HER2 2Rs15d Nanobody Labeled with Ac225

Kanazawa, Japan (UroToday.com) Human Epidermal Growth Factor Receptor type 2 (HER2) is over expressed in many types of human cancer such as breast, ovarian, and colorectal cancers. Whole monoclonal antibodies targeted to HER2 might seem like powerful vectors for radioimmunotherapy but their slow pharmacokinetics and normal tissue clearance are significant disadvantages.

TAT-10: Preclinical Evaluation of Astatinated Nanobodies for Targeted Alpha Therapy

Kanazawa, Japan (UroToday.com) This study has some similarities to the previous paper in that the nanobody (Nb) 2Rs15d-Nb is employed to target HER2+ SKOV-3 cells. The radioisotope is different with present study using the alpha-emitter At211 instead of Ac225.

TAT-10: Development of Alpha-emitting At111-meta-astotbenzylguanidine (At211-MABG) as a Novel Therapeutic Agent for Malignant Pheochromocytoma

Kanazawa, Japan (UroToday.com) Malignant pheochromocytoma (PCC) has previously been treated with the beta-emitter I131 conjugated to meta-iodobenzylguanidine with only limited success since complete remission was quite low. This motivates the present study with alpha-emitting At211-MABG.

TAT-10: Directing Alpha-emitting Conjugates to Cancer Chromatin via PARP-1

Kanazawa, Japan (UroToday.com) Poly (ADP-ribose) Polymerase (PARP-1) is a very abundant nuclear protein. High risk neuroblastoma over-expresses PARP-1 and we plan to use this feature to selectively target the neuroblastoma in treating the cancer chromatin. At211-MM4 was evaluated in vitro for the pharmacology and cytotoxicity in a panel of neuroblastoma cell lines.
Page 2 of 5